News Daily News SOUL: Oral Semaglutide Cuts CV Events in Diabetic Patients L.A. McKeown October 23, 2024
News Daily News Cramming Weekly Physical Activity Into 1 or 2 Days Still Yields Benefits Michael O'Riordan October 03, 2024
News Conference News SCCT 2024 Coronary Calcium Scoring May Help Get Semaglutide to Highest-Risk Patients Todd Neale July 22, 2024
News Daily News Real-world Patients Might Lose More Weight With Tirzepatide vs Semaglutide Yael L. Maxwell July 10, 2024
News Daily News Think You Need a Statin? AHA’s Risk Calculator May Disagree Michael O'Riordan June 28, 2024
News Daily News ‘Provocative’ Projections See Semaglutide Slashing CV Events in Adults With ASCVD Todd Neale June 27, 2024
News Daily News Burden of CVD Still High in UK Despite Prevention Efforts Over 20 Years Yael L. Maxwell June 26, 2024
News Daily News As Trends Reverse in CVD, AHA Warns of Soaring Costs and Illness L.A. McKeown June 05, 2024
News Daily News Tirzepatide Eases Obstructive Sleep Apnea in Patients With Obesity Todd Neale April 17, 2024
News Daily News One in Three Overweight MI Patients May Benefit From Semaglutide Todd Neale February 26, 2024
News Daily News BMI Mostly Doesn’t Impact DOACs, Except Maybe at the Extremes Todd Neale February 02, 2024
News Daily News Universal Risk Tool Works Well in Both Primary and Secondary Prevention Michael O'Riordan February 01, 2024
News Daily News Who Benefits Most From Semaglutide and How Long Will That Take? Shelley Wood December 19, 2023
News Daily News ‘Smoldering Epidemic’ of CVD Risk Factors in Middle-Aged Adults Michael O'Riordan November 21, 2023
News Conference News AHA 2023 New CVD Risk Tool Can Spur Even Earlier Talk About Prevention Yael L. Maxwell November 14, 2023
News Conference News AHA 2023 Full SELECT Results Affirm CV Risk Reduction With Semaglutide in Nondiabetics Todd Neale November 11, 2023